Tributylstannane


Curated chemical-disease associations from CTD
Disease IDDisease nameReference
MESH:D000072660 Teratozoospermia PMID:32783468
MESH:D000505 Alopecia PMID:27310180
MESH:D000857 Olfaction Disorders PMID:20674648
MESH:D001008 Anxiety Disorders PMID:38670349
MESH:D001284 Atrophy PMID:21477642; PMID:28161095; PMID:33720505
MESH:D001941 Breast Diseases PMID:38936095
MESH:D002357 Cartilage Diseases PMID:36319700
MESH:D003872 Dermatitis PMID:27310180
MESH:D003921 Diabetes Mellitus, Experimental PMID:28397090
MESH:D005119 Extravasation of Diagnostic and Therapeutic Materials PMID:24055800
MESH:D005234 Fatty Liver PMID:23322813; PMID:28397090; PMID:29675927
MESH:D005355 Fibrosis PMID:28161095
MESH:D005497 Follicular Cyst PMID:29908848
MESH:D006130 Growth Disorders PMID:25802986
MESH:D006946 Hyperinsulinism PMID:28161095; PMID:31306684
MESH:D006948 Hyperkinesis PMID:2046631
MESH:D006949 Hyperlipidemias PMID:29675927
MESH:D006965 Hyperplasia PMID:38936095
MESH:D007035 Hypothermia PMID:36638932
MESH:D007247 Infertility, Female PMID:28161095
MESH:D007249 Inflammation PMID:25819109; PMID:28161095
MESH:D007333 Insulin Resistance PMID:28180948; PMID:28397090; PMID:30172001; PMID:31306684
MESH:D007859 Learning Disabilities PMID:2046631
MESH:D008206 Lymphatic Diseases PMID:21477642
MESH:D008569 Memory Disorders PMID:35295135
MESH:D009336 Necrosis PMID:25062436
MESH:D009393 Nephritis PMID:27521499
MESH:D009410 Nerve Degeneration PMID:23743147; PMID:26961604
MESH:D009845 Oligospermia PMID:32783468
MESH:D010048 Ovarian Cysts PMID:29908848; PMID:31129395
MESH:D010049 Ovarian Diseases PMID:28161095; PMID:29191790
MESH:D010922 Placenta Diseases PMID:33720505
MESH:D011041 Poisoning PMID:26418422
MESH:D011297 Prenatal Exposure Delayed Effects PMID:23322813
MESH:D011507 Proteinuria PMID:27521499
MESH:D014591 Uterine Diseases PMID:28161095
MESH:D014770 Virilism PMID:29191790
MESH:D015430 Weight Gain PMID:24899383; PMID:25819109; PMID:28161095; PMID:28397090; PMID:29675927; PMID:29908848; PMID:30172001
MESH:D015431 Weight Loss PMID:23743147; PMID:31129395; PMID:38670349
MESH:D018149 Glucose Intolerance PMID:28161095; PMID:28180948; PMID:29675927; PMID:31306684
MESH:D018248 Adenoma, Liver Cell PMID:31939706
MESH:D019457 Chromosome Breakage PMID:31401084
MESH:D019954 Neurobehavioral Manifestations PMID:25499138
MESH:D020567 Fetal Weight PMID:33720505
MESH:D020964 Embryo Loss PMID:26712470; PMID:29191790; PMID:33720505
MESH:D024821 Metabolic Syndrome PMID:29675927
MESH:D050171 Dyslipidemias PMID:30172001
MESH:D051437 Renal Insufficiency PMID:27521499
MESH:D056486 Chemical and Drug Induced Liver Injury PMID:27310180
MESH:D065626 Non-alcoholic Fatty Liver Disease PMID:31939706

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.